- Home
- NMS vs OKUR Comparison
NMS vs OKUR Comparison
Compare NMS & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- OKUR
- Stock Information
- Founded
- NMS 1993
- OKUR 2011
- Country
- NMS United States
- OKUR United States
- Employees
- NMS N/A
- OKUR N/A
- Industry
- NMS Finance Companies
- OKUR
- Sector
- NMS Finance
- OKUR
- Exchange
- NMS Nasdaq
- OKUR NYSE
- Market Cap
- NMS 71.8M
- OKUR 76.6M
- IPO Year
- NMS N/A
- OKUR N/A
- Fundamental
- Price
- NMS $12.30
- OKUR $4.62
- Analyst Decision
- NMS
- OKUR Strong Buy
- Analyst Count
- NMS 0
- OKUR 4
- Target Price
- NMS N/A
- OKUR $33.75
- AVG Volume (30 Days)
- NMS 12.0K
- OKUR 33.0K
- Earning Date
- NMS 01-01-0001
- OKUR 03-10-2025
- Dividend Yield
- NMS 4.11%
- OKUR N/A
- EPS Growth
- NMS N/A
- OKUR N/A
- EPS
- NMS N/A
- OKUR N/A
- Revenue
- NMS N/A
- OKUR N/A
- Revenue This Year
- NMS N/A
- OKUR N/A
- Revenue Next Year
- NMS N/A
- OKUR $33.33
- P/E Ratio
- NMS N/A
- OKUR N/A
- Revenue Growth
- NMS N/A
- OKUR N/A
- 52 Week Low
- NMS $9.21
- OKUR $4.56
- 52 Week High
- NMS $12.18
- OKUR $20.00
- Technical
- Relative Strength Index (RSI)
- NMS 37.62
- OKUR N/A
- Support Level
- NMS $12.35
- OKUR N/A
- Resistance Level
- NMS $12.40
- OKUR N/A
- Average True Range (ATR)
- NMS 0.07
- OKUR 0.00
- MACD
- NMS -0.01
- OKUR 0.00
- Stochastic Oscillator
- NMS 0.00
- OKUR 0.00
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.